The DOI matches its Crossref record.
Adaptation of N-Methyl-D-Aspartate (NMDA) Receptors following Antidepressant Treatment: Implications for the Pharmacotherapy of Depression
Abstract
NMDA antagonists mimic the effects of clinically effective antidepressants in both preclinical tests predictive of antidepressant action and procedures designed to model aspects of depressive symptomatology. These findings led to experiments demonstrating that chronic administration of NMDA antagonists to rodents results in a downregulation of cortical beta-adrenoceptors, a phenomenon also observed following chronic treatment with many antidepressants. These neurochemical and behavioral similarities between antidepressants and NMDA antagonists prompted us to examine the impact of chronic antidepressant treatment on NMDA receptors. Chronic (14 days) but not acute (1 day) administration of seventeen different antidepressants to mice produced adaptive changes in radioligand binding to NMDA receptors. Detailed studies with three antidepressants (imipramine, citalopram, and electroconvulsive shock) show that these changes develop slowly, persist for some time after cessation of treatment, and (for imipramine and citalopram) are dose dependent. Moreover, following chronic treatment with imipramine, these changes in radioligand binding to NMDA receptors appear restricted to the cerebral cortex. Based on the consistency of these effects across antidepressant treatments, we propose that adaptive changes in NMDA receptors may be the final common pathway for antidepressant action. The recent demonstration (Nowak et al., 1995) that radioligand binding to NMDA receptors is altered in frontal cortex of suicide victims (compared to age and post-mortem interval matched controls) is consistent with the hypothesis (Trullas and Skolnick, 1990) that this family of ligand gated ion channels is involved in the pathophysiology of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711
“NMDA receptor is implicated in depression state, which is strongly related to the glutamatergic system as recently demonstrated [63].”
BackgroundChoudary, P. V., Molnar, M., Evans, S. J., Tomita, H., Li, J. Z., Vawter, M. P., Myers, R. M., Bunney, W. E., Akil, H., Watson, S. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507901102 · Cited by 652
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001021 · Cited by 553
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Manji, H. K., Quiroz, J. A., Sporn, J., Payne, J. L., Denicoff, K., A. Gray, N., Zarate, C. A., & Charney, D. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00117-3 · Cited by 505
Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders
Yüksel, C., & Öngür, D. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.016 · Cited by 493
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468
“In rodent studies, pharmacologic- and stress-induction paradigms that lead to depressive-like behaviors have been associated with alterations in cortical glutamate (Glu) (1–3), findings that have been reversed by monoaminergic antidepressants and electroconvulsive therapy (4,5).”
Garcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Barbosa, L. M., Andreazza, A. C., Stertz, L., Fries, G. R., Gavioli, E. C., Kapczinski, F., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.027 · Cited by 454
Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.005 · Cited by 421
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
Furey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417
Glutamate and Depression: Clinical and Preclinical Studies
PAUL, I. A., & SKOLNICK, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.016 · Cited by 408
Self-citationGlutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
Self-citationMcGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
Miller, O. H., Yang, L., Wang, C.-C., Hargroder, E. A., Zhang, Y., Delpire, E., & Hall, B. J. (2014) · eLife · doi:10.7554/elife.03581 · Cited by 358
Efficacy of Antidepressants as Analgesics: A Review
Dharmshaktu, P., Tayal, V., & Kalra, B. S. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010394852 · Cited by 326
Tatarczyńska, E., Kłodzińska, A., Chojnacka‐Wójcik, E., Pałucha, A., Gasparini, F., Kuhn, R., & Pilc, A. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703923 · Cited by 314
Group I metabotropic glutamate receptors: implications for brain diseases
Bordi, F., & Ugolini, A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00095-1 · Cited by 295
Burgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
Drevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219
Small-Dose Ketamine Improves the Postoperative State of Depressed Patients
Kudoh, A., Takahira, Y., Katagai, H., & Takazawa, T. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200207000-00020 · Cited by 189
Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology
Goodnick, P. J., & Goldstein, B. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003021 · Cited by 183
Ketamine as a Novel Antidepressant: From Synapse to Behavior
Murrough, J. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.244 · Cited by 172
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
“Early work by Skolnick and colleagues implicated the glutamatergic system in depression [7], and research over the past three decades further implicated the NMDA receptor in modulating the molecular and cellular processes important for synaptogenesis and neuroplasticity [8].”
BackgroundAstrocyte, a Promising Target for Mood Disorder Interventions
Zhou, X., Xiao, Q., Xie, L., Yang, F., Wang, L., & Tu, J. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00136 · Cited by 120
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131
“As a result, reversal of stress- induced changes has been linked to an antidepressant-like response to monoaminergic modulation, as well as to electroconvulsive therapy (ECT) [31, 32].”
InfluentialThe N-methyl-d-aspartate receptor, synaptic plasticity, and depressive disorder
Petrie, R. X. A., Reid, I. C., & Stewart, C. A. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00063-2 · Cited by 129
Csölle, C., Baranyi, M., Zsilla, G., Kittel, Á., Gölöncsér, F., Illes, P., Papp, E., Vizi, E. S., & Sperlágh, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066547 · Cited by 128
Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12718 · Cited by 121
McCleane, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822020-00005 · Cited by 109
Csölle, C., Andó, R. D., Kittel, Á., Gölöncsér, F., Baranyi, M., Soproni, K., Zelena, D., Haller, J., Németh, T., Mócsai, A., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001933 · Cited by 108
“…disorders (Meador-Woodruff et al. 2001; Toro & Deakin, 2005), the antidepressant properties of glutamate receptor antagonists and modulators (Sanacora et al. 2008) and the regulation of glutamate receptor subunits by clinically used antidepressants (Nowak et al. 1998; Skolnick et al. 1996).”
BackgroundSchipke, C. G., Heuser, I., & Peters, O. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.06.005 · Cited by 98
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Kim, Y.-K., & Na, K.-S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.009 · Cited by 84
The influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75
Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex
Tokarski, K., Bobula, B., Wabno, J., & Hess, G. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.03.007 · Cited by 65
Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test
Młyniec, K., Davies, C. L., Budziszewska, B., Opoka, W., Reczyński, W., Sowa-Kućma, M., Doboszewska, U., Pilc, A., & Nowak, G. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70852-6 · Cited by 63
Self-citationDe Kock, C. P. J., Cornelisse, L. N., Burnashev, N., Lodder, J. C., Timmerman, A. J., Couey, J. J., Mansvelder, H. D., & Brussaard, A. B. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.115311 · Cited by 55
Donello, J. E., Banerjee, P., Li, Y.-X., Guo, Y.-X., Yoshitake, T., Zhang, X.-L., Miry, O., Kehr, J., Stanton, P. K., Gross, A. L., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy101 · Cited by 50
“Glutamatergic neurotransmission and N-methyl-D-aspartate receptors (NMDARs) play important roles in activity-dependent synaptic plasticity, learning, and psychiatric disorders (Skolnick et al., 1996; Wiescholleck and Manahan-Vaughan, 2013; Gerhard et al., 2016).”
BackgroundOh, S. J., Ahn, H., Jung, K.-H., Han, S. J., Nam, K. R., Kang, K. J., Park, J.-A., Lee, K. C., Lee, Y. J., & Choi, J. Y. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01485-w · Cited by 50
The dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression
Rubio-Casillas, A., & Fernández-Guasti, A. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0066 · Cited by 49
Rantamäki, T., & Kohtala, S. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018697 · Cited by 45
Govoni, S., Racchi, M., Masoero, E., Zamboni, M., & Ferini-Strambi, L. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000801 · Cited by 35
Opler, L. A., Opler, M. G. A., & Arnsten, A. F. T. (2016) · CNS Spectrums · doi:10.1017/s1092852914000686 · Cited by 28
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Feng, M., Crowley, N. A., Patel, A., Guo, Y., Bugni, S. E., & Luscher, B. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.003 · Cited by 20
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.003 · Cited by 18
Hayley, A., Green, M., Downey, L., Keane, M., Kostakis, P., & Shehabi, Y. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4842-7 · Cited by 10
Metadata
- Authors
- Skolnick, P., Layer, R., Popik, P., Nowak, G., Paul, I., & Trullas, R.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 1996-01
- Volume
- 29
- Issue
- 01
- Pages
- 23-26
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W1988244113
- Cited by
- 344
- References
- 0
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.